R. Vassilopoulou-sellin et al., Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively, J CL ONCOL, 17(5), 1999, pp. 1482-1487
Purpose: to determine whether estrogen replacement therapy (ERT) alters the
development of new or recurrent breast cancer in women previously treated
for localized breast cancer.
Patients and Methods: Potential participants (n = 319) in a trial of ERT af
ter breast cancer were observed prospectively for at least 2 years whether
they enrolled onto the randomized trial or not. Of 319 women, 39 were given
estrogen and 280 were not given hormones. Tumor size, number of lymph node
s, estrogen receptors, menopausal status at diagnosis, and disease-free int
erval at the initiation of the observation period were comparable for the t
rial participants (n = 62) versus nonparticipants (n = 257) and for women o
n ERT (n = 39) versus controls (n = 280). Cancer events were ascertained fo
r both groups.
Results: Patient and disease characteristics were comparable for the trial
participants versus nonparticipants, as well as for the women on ERT versus
the controls, One patient in the ERT group developed a new lobular estroge
n receptor-positive breast cancer 72 months after the diagnosis of a ductal
estrogen receptor negative breast cancer and 27 months after initiation of
ERT. In the control group, there were 20 cancer events: 14 patients develo
ped new or recurrent breast cancer at a median time of 139.5 months after d
iagnosis and six patients developed other cancers at a median time of 122 m
onths.
Conclusion: ERT does not seem to increase breast cancer events in this subs
et of patients previously treated for localized breast cancer. Results of r
andomized trials are needed before any changer in current standards of care
can be proposed, J Clin Oncol 17:1482-1487. (C) 1999 by American Society o
f Clinical Oncology.